Magnifying NBI Endoscopy for Gastric Condition

Magnifying Narrow-band Imaging for Diagnosis of H. Pylori and Precancerous Gastric Conditions: Comparison With Standard Endoscopy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04489030

Enrollment

254

Registered

2020-07-28

Start date

2016-06-01

Completion date

2020-08-31

Last updated

2020-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastritis H Pylori

Brief summary

Recently, the improved resolution with standard endoscopy allows the close observation of highly inflamed gastric mucosa without a magnifying view. In a previous study, the investigators established the endoscopic classification of H. pylori-infected stomach by non-magnifying standard endoscopy. One normal RAC pattern and three types of abnormal patterns were observed. Overall diagnostic accuracy for predicting H. pylori-infection was 91.6%. However, there is no comparison study predicting H. pylori-infection and precancerous gastric lesions between standard and magnifying endoscopy.

Detailed description

The investigators aimed to evaluate the diagnostic efficacies of non-magnifying standard endoscopy for predicting H. pylori-infection status and precancerous gastric conditions, compared to magnifying NBI endoscopy

Interventions

OTHERMagnifying narrow-band imaging endoscopy

During endoscopy, gastric mucosal patterns would be examined by magnifying narrow-band imaging.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Gastroscopy can be performed * H. pylori test and pathological analysis can be performed

Exclusion criteria

* Age \< 20 or \> 70 years * Anemia (serum hemoglobin level \< 10 g/dL) * Severe systemic disease * Advanced chronic liver disease * Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics * History of H. pylori eradication * History of gastric surgery * Recent history of upper gastrointestinal bleeding

Design outcomes

Primary

Measure	Time frame	Description
H. pylori infection status	1 month	H. pylori positivity would be assessed using rapid urease test.
Degree of chronic gastritis	1 month	Gastric atrophy and intestinal metaplasia would be evaluated on the basis of histopathological examination (updated Sydney system).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026